Amgen Outlines Long-Term Strategy
5.03.2013Company: Amcham
Amgen Emphasizes Pipeline, International Expansion and Biosimilars as Growth Drivers / Pivotal Data from Eight Late-Stage Programs Anticipated Between 2013 and 2016
Amgen (NASDAQ:AMGN) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City.
Robert A. Bradway, chairman and chief executive officer at Amgen, opened the meeting by affirming the company's core strategy will continue to focus on innovation, discovery and development of breakthrough molecules to address significant unmet medical needs, and manufacturing of high-quality biologics. Bradway highlighted how certain elements of the company's strategy have evolved:
- Research and Development (R&D): A more selective approach to R&D, embracing a "pick the winners" strategy with greater focus on human genetics to identify and validate targets, and a strong commitment to return on capital;
- Commercial: Transformation of the commercial model with an emphasis on expanded access and value to payers, increased presence in key new and emerging markets, investment in new growth opportunities, including biosimilars, and greater product differentiation through drug delivery devices; and
- Manufacturing: Emphasis on new manufacturing processes and technologies, driving expanded throughput and flexibility and lower capital needs.
"Amgen is in a unique position to capitalize on major advances in drug discovery and biologics manufacturing," said Bradway. "We are making strategic investments to drive long-term growth and deliver for both patients and shareholders."
To get more information about Amgen´s strategy click at http://www.amgen.com/media/media_pr_detail.jsp?year=2013&releaseID=1782715
